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There exists a lack of accurate, reproducible three-dimensional dosimetry techniques for 
stereotactic radiosurgery (SRS) commissioning and quality assurance. This experiment 
evaluates the use of ClearView gel dosimeters as an alternative to current methods for 
small field dosimetry in SRS testing. ClearView differs from other gel dosimeters in that 
it uses tetrazolium salt in its chemical make-up in place of traditional Fricke-type 
compounds. Using a Varian TrueBeam radiotherapy system to deliver the radiation, three 
vials of ClearView gel dosimeter were tested in three different dose delivery scenarios. 
The first test examined the dosimeter’s response to a static beam with the dose isocenter 
targeted to the centroid of the vial. The second evaluation consisted of a full rotational 
SRS delivery about thecenter of the dosimeter. Lastly, a complete end-to-end treatment 
plan was performed to evaluate the accuracy of the dosimeter in a full SRS procedure. 
The three dosimeters were then scanned to measure the dose distribution throughout the 
gel. Finally, the resulting datawas compared to the initial treatment plan to determine the 
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accuracy of the gel. According to the comparisons performed, the ClearView gel showed 
capability of sub-millimeter spatial accuracy across the three evaluations, with a 
maximum geometric uncertainty of 1.2 mm. Based on these results, ClearView gel 
showspromise for possible use in SRS dosimetry applications in clinical settings.
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Stereotactic radiosurgery (SRS), also known as stereotactic radiotherapy (SRT), is 
an increasingly common technique for treating intracranial tumors or other small target 
areas. In SRS, high doses of radiation are delivered with very steep falloffs outside of the 
target area, saving the healthy tissue surrounding the target [1]. Further advancements in 
SRS with rotational delivery allow for even more accuracy and target precision for 
treatment of exceedingly small targets [2].On average, typical prescribed doses can range 
from 15 – 21 Gy for SRS treatment of cancerous tumors within the brain, with individual 
beams of up to 50 Gy [3, 4]. With this high amount of dose being delivered to such 
concentrated areas, it is of great importance that the treatment dose be accurately 
delivered only to the target area for the safety of the patient. 
In order to ensure accurate, safe patient treatmentwith stereotactic radiosurgery, a 
quantifiable form of dose measurement is crucial in the commissioning processfor SRS 
systems [5]. Commissioning is the first step in determining the viability of a new SRS 
system after installation, which examines four basic areas of SRS: precision, localization, 
dose distribution, and patient safety [6].A test of precision determines whether or not the 
system is able to hit the target area within an established amount of spatial uncertainty 
calculated for the machine. Localization can then be verified by ensuring that the dose 
delivered to the target does not exceed the target area. Within this area, dose distribution 
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can be examined to determine how the dose of the system would be distributed in human 
tissue. Finally, patient safety is carefully monitored throughout the testing procedure to 
ensure that no extraneous dose is delivered and outside sources of interference are 
limited. After these four properties of a new SRS system have been deemed acceptable 
by a Qualified Medical Physicist, the system must then be continually tested to ensure 
that the machine stays within the acceptable limits, a process known as Quality 
Assurance (QA) [7]. 
QA tests are essential to SRS systems in order to reduce accidents as well as 
identify possible sources of errors in treatments, so the methods to evaluate these systems 
must have the capability to examine every aspect of SRS treatment in question [7]. As 
stated earlier, SRS systems have the capability to rotate about very small target volumes 
during delivery of very high doses. Due to this unique property of SRS treatments, the 
resulting dose distribution can become difficult to quantify accurately, requiring an 
extensive quality control procedure to ensure SRS accuracy [7, 8, 9, 10]. 
An integral part of the quality control procedure is the choice of the radiation 
detector used for dose determination. Several different types of two-dimensional(2D) 
detectors have been utilized for SRS, including ion chambers, radiographic films, and 
semiconductor detectors [4, 11, 12, 13]. An overview of the usability and accuracy of 





1.1 Traditional2D Detectors 
1.1.1 Ion Chamber 
Perhaps the most traditional type of 2Dradiation detector used for SRS dosimetry 
is the ionization chamber. Typical ion chambers consist of two electrodes across a 
voltage gradient separated by a gas-filled cavity inside the chamber. Incoming ionizing 
radiation creates ion pairs within the gas, causing a flow of charge when the charged ions 
are accelerated to the oppositely-charged electrodes. This flow of charge can then be 
measured to quantify the amount of incoming ionizing radiation. 
In the past, ion chamber size has been a limiting factor for SRS applications, with 
physical diameters too large for the small field sizes utilized in SRS treatments [8, 
14].When the diameter of the detector is comparable to the field size used in SRS 
delivery, precise determination of the dose isocenter location can be difficult if even 
possible without averaging.However, the development of micro ion chambers has 
improved the usability of ion chambers for SRS systems, though averaging can still occur 
[4, 15], allowing measurement of dose distribution in smaller fields. Additionally, both 
ion chambers and micro ion chambers suffer from a lack of spatial resolution for the high 
dose falloffs and intensities required in SRS dosimetry [4, 16]. 
Finally, another difficulty when using ion chambers for SRS QA is how the beam 
interacts with the gas medium inside the ionization chamber itself. Since human tissue is 
much more equivalent to water than air, certain ion chambers differ fundamentally in the 
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reported dose rate to the dose that would be received by tissue [8]. Therefore, an extra 
step must be applied to correct for this difference after the data has been acquired. 
1.1.2 Radiographic Film 
Another common detector for current SRS QA methods aside from ion chambers 
is radiographic film. Basic radiographic film consists of an emulsive layer applied to a 
base with a protective coating sealing the emulsion. Though films can differ greatly in 
type (single emulsion or double emulsion, intensifying screen or non-intensifying screen), 
common films interact with incoming ionizing radiation through the emulsion applied on 
the base. Silver halide crystals suspended within the emulsion interact with the incoming 
radiation and store the energy until the film is developed. The dose data from the 
developed film can then be determined through measuring optical density (OD). 
Radiographic films offer much higher spatial resolution than most ion chambers, 
which is beneficial due to the steep dose gradients used in SRS treatments [4, 8, 
17].However, non-reproducibility is a problem for some applications using radiographic 
films [4, 8, 15]. Reproducibility is limited for radiographic films dues to several factors 
during manufacturing and exposure to radiation. Films can differ individually due to 
inhomogeneities during the manufacturing process, during which crystals in the emulsive 
layer are randomly distributed across the film. This distribution can lead to slight 
variations in interaction to incoming radiation which in turn leads to different OD 
readings after development. Air pockets inside the protective packaging to shield the film 
from external light can also cause inhomogeneities in OD readout [15]. Finally, film 
orientation in relation to the source also contributes to reproducibility of radiographic 
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films in SRS. Though these limitations can be overcome or simply deemed negligible in 
medical imaging procedures, they are too great for consistent use in small field 
dosimetry, especially in SRS commissioning and QA. 
1.1.3 Semiconductor Detectors 
 Semiconductors such as diode detectors and metal oxide semiconductor field 
effect transmitters (MOSFET) have also been used for SRS dosimetry. Semiconductor 
detectors offer small size and can be arranged in arrays for increased spatial resolutions, 
and they offer real-time data acquisition [10, 15, 18]. Unfortunately, diode detectors 
suffer from temperature dependence and directional dependence in relation to the 
source.Also, much like radiographic films, both diode detectors and MOSFETs suffer 
from reproducibility issues as well due to orientation in relation to the source [14, 15]. 
Tissue equivalency is also a disadvantage shown by diodes much like ion chambers [8, 
18]. 
 Recently, a new type of semiconductor detector has emerged for SRS dosimetry: 
diamond detectors. Developments in production of synthetic diamond have allowed for 
the production of small synthetic diamonds for use in dose measurement systems in place 
of silicon diodes [10]. Although diamond detectors can be considered soft-tissue 
equivalent and energy independent, they have the issue of being dose rate dependent, 
requiring calculated corrections to account for this dependence [8, 10]. 
1.1.4 Thermoluminescent Dosimeters 
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 Thermoluminescent dosimeters (TLD) are another radiation detector type used for 
dosimetry in clinical applications. This detector type reacts with ionizing radiation by 
emitting light proportional to the amount of energy received by the incoming radiation. 
TLDs can be created in small sizes and arranged in arrays much like diode detectors, 
allowing for a high spatial resolution [19].Some types of TLDs also are largely tissue 
equivalent, which allows for closer simulation ofhow dose would be distributed in human 
tissue during treatment [14, 18]. The biggest problem with TLDs is that, similarly to both 
films and semiconductors, TLDs suffer from issues in reproducibility and consistency[8, 
14]. 
1.2 Gel Dosimeters 
All of the above detectors each have individual benefits for use in SRS 
commissioning and QA.However, one large drawback to all of the above detectors is 
their ability to only capture data in two dimensions.Many detectors, such as ion 
chambers, radiographic films, and diodes also are highly dependent on the incoming 
beam energy, with films, diodes, and diamond detectors also affected by the rate at which 
the dose is being delivered [8, 14, 15]. In addition, some of the above detector types are 
limited in the amount of dose that they can measure. 
For these reasons, gel dosimetry has emerged as a promising method for ensuring 
three-dimensional SRS dose accuracy [9, 11, 20, 21]. The ability to measure dose 
delivery in three dimensions allows for precise determination of the isocenter from the 
machine’s output. Currently, two main types of gel dosimeters are common for this 




1.2.1 Fricke Gel Dosimeters 
 In 1927, Fricke explored early chemical dosimetry dealing with ferrous-sulphate 
solutions for radiation detection [22]. When irradiated, the ferrous Fe
2+
 ions embedded in 
the solution will transform into ferric Fe
3+
 ions [22]. After the emergence of three 
dimensional imaging techniques such as nuclear magnetic resonance imaging (MRI), 
Gore proposed further developing Fricke’s techniques to obtain dosimetry for three 
dimensional applications [23, 24]. To accomplish this, aqueous Fricke-type solutions 
were fused into gels to form three dimensional gel dosimeters, which could then be 
scanned by MRI techniques to obtain dosimetry information [25]. 
 In addition to MRI interpreted results, xylenol orange is now commonly added to 
the Fricke-typegel solutions as a different data technique. These Fricke-types of 
dosimeters will develop a visible color change upon irradiation and subsequent Fe
3+
 ion 
production [26]. This visible color change can then be scanned asOD measurements, 
which exhibits a linear relationship with the amount of dose received by the gel [27]. 
These types of Fricke gels are convenient in that they can be imaged on site at clinics 
where MR imagers are not present [24]. 
 Fricke-type gel dosimeters originally suffered from a disadvantage of low 
sensitivity, with linear responses up to approximately 10 Gy [25, 27]. However, doses of 
up to 40 Gy may result in linear dose relationships if the gel is purged with oxygen prior 
to irradiation [28]. This limitation poses a problem for modern SRS techniques, in which 
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higher doses may be delivered during treatment. Additionally, chemical instability of 
Fricke gels poses another issue for dosimetry, which causes a degradation of the retained 
dose information over time [29]. The diffusion of the Fe
3+ 
ions after irradiation eventually 
destroys the spatial resolution contained by the gel [24]. In order to overcome these 
limitations, physicists and chemists alike are exploring the development of other types of 
gel dosimeters. In addition to the development of polymer gel dosimeters as discussed 
below, another type of gel dosimeter based on the chemistry of tetrazolium salts, 
ClearView, will be discussed later in section 1.2.3. 
1.2.2 Polymer Gel Dosimeters 
 Another type of common gel dosimeter is a polymer gel dosimeter, which will be 
briefly discussed here. Polymer gel dosimeterswere first discussed well after the 
emergence of Fricke-type gels. The first step in polymer gel dosimetry occurred in 1957 
when works by Andrews examined the effects of ionizing radiation on 
polymethylmethacrylate [30]. Following this study, investigations into polymers for 
dosimetry showed promise for development of a polymer-type dosimeter.In 1992, a new 
type of polymer gel dosimeter under the acronym BANANA emerged, named after its 
chemical makeup (bis, acrylamide, nitrous oxide, and agarose) [20]. Later, the agarose 
component was replaced with aqueous gelatin under the generic acronym PAG. 
Polymer gels exhibit high reproducibility in terms of dose response and 
distribution and also have the capability of minimal dose rate dependence [31]. Unlike 
Fricke-type dosimeters, these gels use the properties of radiation-induced polymerization 
and cross-linking of acrylic monomers and in turn do not suffer from the diffusion 
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problem associated with Fricke gels [11, 20]. However, oxygenation issues posed a 
problem for early polymer dosimeters, requiring the dosimeters to be manufactured in an 
oxygen free environment. This issue was later remedied by a new formulation of polymer 
gels under the acronym MAGIC (methacrylic acid, ascorbic acid, gelatin, and copper), 
though limited studies have looked into their use for dosimetry over Fricke-type gels 
[20]. 
1.2.3 ClearView Gel Dosimeter 
The dosimeter used in this experiment is ClearView gel dosimeter by Modus 
Medical Devices, Inc. (Ontario, Canada). As stated previously, ClearView differs from 
other gel-type dosimeters in that it is based on tetrazolium salt chemistry, which was 
originally conceived for use in liquids and films. The composition of the gel features less 
than one percent of the tetrazolium salt suspended within glycerol (10 vol. %) in water 
with a gellan gum gelling agent (1.25 wt. %). This combination of compounds results in a 
gel with a physical density of 1.02 g/cm
3
, which is very close to the density of water. 
Due its specific composition, this new type of gel exhibits a strong linear 
relationship between absorbed dose and OD of the irradiated gel within ranges of 10-80 
Gy. This useful range of linear operation is much wider than the ranges for Fricke-type 
gels as discussed in the introduction, giving ClearView a much more flexible use for SRS 
treatments. Within this established dose range, higher doses will result in a higher signal 
to noise ratio, with an optimal performance range across the middle of the spectrum. 
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Upon irradiation, the ClearView gel will exhibit a purple hue proportional to the 
dose received, with doses of more than 20 Gy resulting in a change visible to the eye. The 
more radiation the gel receives, the darker the shade of purple the gel displays. This color 
change is due to the chemical formation of a formazan dye within the gel upon ionization. 
Increased radiation absorption correlates directly to an increased formation of the dye, 
hence the deepening of the purple shade after more intense irradiation. A manufacturer 
recommended development time of 45 minutes after irradiation ensures that the dose 
information stored in the dye has time to fully darken in areas where dose has been 
concentrated. The development process does not require any additional work by the user, 
just that the gel be allowed to remain at room temperature during the 45 minute period as 
the chemical reactions in the gel stabilize. 
Once irradiated, the purple shade will remain permanently fixed in place within 
the gel, thus retaining all of the information regarding dose applied to the dosimeter. Due 
to this permanent change, each vial of ClearView gel is designed for a single use. Though 
spatially and chemically stable, biological contaminants may form in the gel over time, so 
it is best that analysis be conducted within a timely manner after irradiation. Formation of 
these contaminants can be limited by keeping the gel in chilled containers during 
shipping and storage, though irradiation of the gel should occur after the gel has warmed 
to room temperature. The irradiated gel can then be scanned at the manufacturer’s facility 
using an opticalcomputed tomography (CT) scanner to interpret the OD values of the gel 
and relate them to the amount of ionizing radiation received. 
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This experiment will examine several factors of ClearView gel such as its 
response to dose delivery and its capability for high spatial resolution in SRS QA. Other 
aspects such as energy dependence, dose rate dependence, temperature dependence have 
been untested at the time of this experiment, but pose viable options for future research. 
2.0 MATERIALS AND METHODS 
2.1 Planning 
 For this experiment, three vials of ClearView gel dosimeter were provided from 
Modus Medical Devices, Inc. With these three dosimeters, the goal was to create and 
carry out three effective tests to examine the use of ClearView as a clinical gel dosimeter 
for commissioning and quality assurance in SRS. After several different possibilities 
were examined, three different scenarios were selected to test the gel’s capabilities as an 
effective dosimeter. 
The first evaluation would serve to test the gel’s accuracy of dose distribution for 
a simple, static electron beam targeted through the center of the vial. Since the optimal 
range of the gel was centered near 40 Gy as discussed earlier, the plan was to deliver a 
total matching isocenter dose of 40 Gy to the first dosimeter. The results of this 
irradiation would then show how the dosimeter reacts to dose delivery with minimal 
outside factors influencing the irradiation. 
The second evaluation of the ClearView gel would expand upon the first 
evaluation’s 40 Gy static delivery. However, in this evaluation, the static beam would be 
replaced by a rotational delivery technique.As discussed earlier in the introduction, new 
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SRS systems possess the ability to rotate about the target in a 360 degree arc. The 
treatment plan would utilize this feature to irradiate the gel in a full rotation about the 
second dosimeter to deliver the 40 Gy dose. 
With the first two evaluations examining the gel’s performance with basics of 
SRS dose delivery, the third evaluation should then examine a more in-depth treatment 
plan. To accomplish this, it was decided that a full end-to-end SRS treatment test would 
best explore the possibility of using ClearView gel dosimeters for clinical commissioning 
and quality assurance. Again, a 40 Gy dose would be delivered for consistency across my 
evaluations, though the methods to deliver this dose would shift as needed to account for 
the newly-introduced patient geometry and density. 
In order to most accurately perform the end-to-end test, it was essential to 
simulate the physical make-up of a human patient. To accomplish this, a Phantom 
Laboratory, Inc. (Salem, NY) Model TLP290 RSVP Phantom II head phantom was 
utilized, which could be filled with water to simulate human tissue for SRS purposes 
[32]. With proper positioning, a vial of ClearView at a fixed position within the water-
filled phantom could accurately simulate anintracranial condition. Since intracranial 
tumors are commonly treated using SRS systems, it was decided to simulate a left-sided 
acoustic neuroma by positioning the dosimeter appropriately within the phantom [33]. 
2.2 Preparation 
Upon receiving 3 vials of ClearView gel from the manufacturer, each of the 
sealed vialswas removed from the chilled shipping container and allowed to warm to 
13 
 
Figure 2: ClearView gel dosimeter and adapter 
room temperature. The vials measured 8.5 cm in length and 4.3 cm in diameter, and each 
vial had a wall thickness of 1.0 mm. 
 
 
Once the vials had warmed to room temperature as required,the acrylic 
positioning adapters, which had become disconnected during shipment, were re-attached 
tothe top of each vial. To re-attach each acrylic adapter to the jar lids, a quick-dry epoxy 
was used aftereach of the adapters was carefully aligned to match with the original 
positioning markings on the lid. 
2.3 Procedure 
2.3.1 Evaluation 1 
For the first of the three evaluations, it was decided that a static beam be delivered 
through the centroid of one ClearView vial. The jarwas first mounted to a CIVCO 
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Figure 2: CIVCO Type-S™ Overlay Board with attached headrest 
Medical Solutions (Orange City, IA) 20-CFHN-SUB2 Type-S™ Overlay Board to 
prevent movement during the procedure. 
 
 
Once attached, the board was then placed into a General Electric (Fairfield, CT) 
LightSpeed RT CT scanner couch. Initial alignmentof the vial was conducted by 
manually aligning the built-in planar positioning lasers to intersect at the visual center of 
the vial. Using a 120 kVp scan at 10 mA, a quick “scout” scan was performed to verify 
proper placement of the vial. Once positioning was satisfactory, a full helical CT scan of 
the headrest at 120 kVp and 350 mA at 1.25 mm increments was performed. A total of 
133 images were collected in a time of 46 seconds through a 17.5 mm cone beam. 
 The imaging data from the CT scan was then sent to the Varian Medical Systems, 
Inc. (Palo Alto, CA) Eclipse treatment planning system v11.0. This system allowed for 
automatic identification of the scanned object in all three planes: axial, coronal, and 
sagittal. Once the appropriate contour of the vial had been identified, the center of the 
dosimeter was set to the origin of the planes. Through this central region, a single pencil 
beam was assigned to pass through the vial in the Varian Cone Planning software. The 
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Figure 3: Evaluation 1 ClearView dosimeter axes 
beam was designated to be a 6 MV Flattening Filter Free (FFF) beam through a 17.5 mm 
cone. A total dose of 40 Gy to the vial isocenterwas planned to be delivered for a beam-
on time of 4321 MU. The axes of the jar in relation to the beam source are illustrated in 
Figure 3 below. 
 
 
 Once the treatment planning had been completed, the secured vial was transferred 
to the Varian TrueBeam particle accelerator. Again, utilizing three planar lasers to 
position the vial, the visual center of the vialwas set at their intersection. A cone of 17.5 
mm in diameter was attached to the particle accelerator and placed into the path of the 
beam. The room was then cleared, and one static beam was delivered according to the 
treatment plan. Upon completion of beam delivery, the vial was removed from the 
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overlay board and allowed to develop for 45 minutes as mentioned previously before 
being returned to its chilled container. 
2.3.2 Evaluation 2 
 The next evaluation differs fundamentally from the first in that, instead of a single 
static beam, two 180 degree arc beams were implemented as discussed earlier. First, the 
second ClearView jar was mounted to the CIVCO board in the same fashion as in 
Evaluation 1. This assembly was then inserted into the GE LightSpeed CT scanner for 
initial imaging. Again, visual alignment of the vial’s center into the intersection of the 
three beams’ paths ensured that the dosimeter was properly positioned in the scanner. To 
create a treatment plan, the vial was imaged at 120 kVp and 350 mA at 1.25 mm 
increments along the length of the jar. As before, a total of 133 images were collected in 
a time of 46 seconds through a 17.5 mm cone beam. This data was then networked to the 
Varian Eclipse software for treatment planning. 
Once in the treatment planning system, the images were again aligned so that the 
origin of the three planes was aligned on the center of the ClearView vial. For this 
evaluation, two 6 MV FFF beams arcs were programed to rotate around the vial. One 
beam was set to rotate clockwise about the jar from 0 to 180 degrees; the other followed a 
180 degree rotation from center in the counter-clockwise direction to encompass the vial 




Figure 4: Evaluaton 2 ClearView dosimeter axes 
 
 
These two beams were set to deliver a combined total dose of 40 Gyto the isocenter 
through a 15 mm cone. With a successful planning session, the finalized plan was 
exported to the TrueBeam console in preparation for delivery. 
 The 17.5 mm cone from the first evaluation was removed and replaced with a 15 
mm diameter cone to match the new treatment plan. The vial assembly was then placed 
onto the accelerator’s couch in the path of the visual lasers. Using the intersection of the 
three planar beams, the vial was carefully centered under the accelerator. Once the vial 
had been aligned properly, the room was cleared, and the treatment plan was 
administered. Each of the two arc beams delivered their planned dose for an individual 
beam-on time of 2249 MU each. After the beams had delivered their dosage,the vial was 
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Figure 5: Phantom Laboratory head phantom 
detached from the mount, allowed to develop at room temperature for 45 minutes, and 
then returned to the chilled container. 
2.3.3 Evaluation 3 
For the final evaluation, an end-to-end test on the ClearView gel was performed, 
making use of a simulated patient geometry and physical density. To accomplish this, 
aPhantom Laboratory, Inc. RSVP Phantom II head phantom was utilized, which was 
filled with water to simulate human tissue as discussed in the introduction. 
 
 
After filling the phantom with water, preparation of the remaining ClearView gel 
dosimeter began. First, three titanium fiducialswere placed around the surface of the jar 
for planar identification in the treatment planning software. Then, a plastic rod was 
attached at the threaded acrylic adapter. This rod assembly was inserted into the base of 
the phantom at the neck. Finally, the dosimeter was positioned within the phantom to 
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simulate the left-sided acoustic neuroma according to the planned procedure. The 
phantom was then sealed water-tight to prevent formation of air pockets within the head. 
With the dosimeter securely fixed within the phantom, the phantom was attached 
to a Varian Head Frame SRS halo through use of four cranial screws. This head frame 
allowed secure attachment of the head assembly to the couches of both the CT scanner 
and TrueBeam accelerator. Once attached to the CT couch, three additional fiducials 
were positioned along the surface of the phantom at the intersections of the wall-mounted 
positioning lasers. Now, with a frame of reference for the treatment plan, it was time to 
perform the CT scan. At 120 kVp and 350 mA, 149 images were obtained from the 
helical scan at 1.25 mm increments in 51.3 seconds. This image set was then sent to the 
Eclipse treatment planning software. 
Using the two sets of fiducials to align the reference planes, the vial was 
contoured, andthe planned dose isocenter was designated to its center. The Cone Planning 
software allowed for creation ofa plan of four 6 MV FFF beams delivering a 40 Gy dose 
to the ClearView dosimeter isocenter. Using specific gantry rotations in addition to couch 
alignment, these beams were programmed to deliver their dose to the pinpoint target of 
the vial isocenter with spherical dose falloff. The beam plans are outlined in the 






Beam Table Position Gantry Rotation Beam-on Time 
Arc 1 340°
 
30°-120° 1819 MU 
Arc 2 305° 30°-120° 1818 MU 
Arc 3 20° 240°-330° 1462 MU 
Arc 4 55° 240°-330° 1574 MU 
Table 1: Evaluation 3 beam plan 
With these four equally weighted beams, the Varian Aria record-and-verify 
system performed a cone-beam CT (CBCT) before treatment delivery to ensure 
correction of any inaccuracies in phantom alignment on the TrueBeam six-degree of 
freedom (6DOF) couch. This treatment plan was finalized and sent to the TrueBeam 
console. 
The phantom assembly was transferred from the LightSpeed CT scanner to the 
TrueBeam 6DOF couch. Using the visual alignment lasers to position the phantom under 
the center of the accelerator, the phantom was carefully attached to the 6DOF couch. 
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Figure 6: Phantom assembly secured using SRS halo 
 
 
Again, the 15 mm cone was used to deliver the beams in this evaluation. With the 
phantom and ClearView dosimeter in place, the room was cleared in preparation for 
treatment delivery. 
 Once the room was closed, the scheduled 120 kVp CBCT commenced prior to 
dose delivery. Using the 6DOF to adjust as necessary, the system corrected for 
positioning discrepancies between the treatment plan and the initial placement of the 
phantom. After the CBCT had finished and the automatic adjustments were made, each 
of the four beams was delivered according to the finalized treatment plan. Once the 
treatment was complete, the phantom was removed from the couch and drained. After the 
water had been drained, he ClearView gel dosimeter was carefully removed from the 
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phantom and dried. Once developed, the dosimeter was placed with the other two vials in 
the chilled container. 
2.4 Examination 
With the three vials securely packed into the chilled shipping container, the 
package was then shipped back to the manufacturer for scanning. Two days after initial 
treatment delivery, the ClearView vials were scanned at the Modus facility using a Vista 
15 optical CT scanner. This OD scan data was then converted to dose distribution using a 
calibration scan, which is dependent on manufacturing variation of the gels and thus must 
be calibrated for each different batch. This calibrated dose information was then imported 
into the VistaView 3D Visualization Software v.0.3.3 where the distribution can be 
displayed in three dimensions. Finally, these files were sent back forcomparative analysis 
within the VistaView software. 
2.5Sources of Uncertainty 
For each of the three evaluations, several sources of uncertainty had to be taken 
into account. The systematic uncertainties of the evaluations were accounted for in 
similar fashion to the studied of AAPM Task Group 42 [R]. For Evaluations 1 and 2, the 
first source of uncertainty to appear in the trial was the repositioning of the acrylic 
adapter to the lid of the vial. Though the adapter itself was not attached to anything aside 
from the lid itself, the markings on the adapter were later used for adjusting scanner 
alignment at the manufacturer’s facility. Since the adapter was to be used for this purpose 
based on a baseline scan before transit, an attempt to position the 1.0 mm wide markings 
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on the adapter itself to directly align with the markings on the vial’s lid was made. Due to 
this possible misalignment, an uncertainty contribution of δ1 = 1.0 mm was accredited to 
the first evaluations. 
The second source of uncertainty taken into account for the first evaluations was 
the accuracy of the Varian TrueBeam particle accelerator. A Winston-Lutz isocenter test 
was performed to quantify this uncertainty prior to irradiation. On the day of the 
evaluations, a 5 cm
3
 cube with an internally centered fiducial was placed in the 6DOF 
couch under the accelerator. This fiducial was then centered under the crosshairs in the 
light field of the accelerator at several different orientations. From this test, it was 
determined that an additional uncertainty of δ2 = 0.3 mm be included for the gantry 
positioning. Another positioning uncertainty that factors into the final results is the 
manual alignment of the vial using the wall lasers. Although the placement of the vial 
between the CT scanner and the TrueBeam was replicated as uniformly as possible, an 
additional alignment uncertainty of δ3 = 0.25 mm was accounted for in the final 
uncertainty calculations. 
Finally, after the evaluations had been completed, the manufacturer’s reading of 
the ClearView gel data introduced additional uncertainties into the results. As stated 
previously, small markings on the lids of the vials were scanned prior to shipment to 
establish a baseline orientation of the jars within the Vista scanner. When aligning the 
small markings, a stated uncertainty of δ4 = 0.5 mm is proposed by the manufacturer. In 
addition, the wall of the vial itself contributes a significant amount of uncertainty to the 
final results. When scanning the ClearView vial after the dosage has been delivered, 
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several factors can have an effect on the output accuracy. Variables such as wall 
thickness, refractive index, and differences in jar manufacturing can all have noticeable 
effects on the apparent OD of the gel. With all of these scenarios in mind, a possible 
uncertainty of δ5 = 1.0 mm was assigned to the Vista scanner readout. 
To calculate the total uncertainty for my data, each of the individual uncertainties 
from the five sources listed above was squared. Then, the standard deviation by 
quadrature was found by taking the square root of the sum of all the individual squared 
uncertainties. This calculation resulted in a total overall uncertainty of δ = 1.6 mm. The 
sources and results are shown in the following table. 
Uncertainty Source δ (mm) 
Acrylic adapter alignment 1.0 
Winston-Lutz isocenter test 0.3 
Manual laser alignment 0.25 
VistaView scanner alignment 0.5 
VistaView scanner readout 1.0 
Standard deviation by quadrature 1.6 
Table 2: Evaluation 1 and 2 uncertainty sources and values 
The sources and values in Table 2 apply only to Evaluations 1 and 2. For 
Evaluation 3, several of the sources are replaced according to the method of delivery. As 
before, the reattachment of the acrylic adapter introduced an initial uncertainty of δ1 = 1.0 
mm when carefully aligning the markers. Since the adapter was used for attachment of 
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the vial to the positioning rod in this evaluation, realignment was crucial to obtaining 
accurate results. 
Unlike Evaluations 1 and 2, Evaluation 3 utilized not only the rotational 
positioning of the TrueBeam gantry, but also the movement of the 6DOF couch. With 
this additional movement, the Winston-Lutz isocenter test revealed a total uncertainty of 
δ2 = 0.6 mm, a 0.3 mm increase over the gantry rotation alone. In place of the manual 
laser alignment used to position the vials on the first two evaluations, the onboard CBCT 
was utilized in order to align the isocenter of the dose to the centroid of the vial. This 
process has a manufacturer specified uncertainty of δ3 = 0.1 mm for the CBCT and 6DOF 
couch. 
Once again, after the three evaluations had been completed, additional 
uncertainties were introduced during the dosimeter scanning process at the manufacture’s 
facility. Alignment of the small markings on the top of the vial contributed an alignment 
uncertainty of δ4 = 0.5 mm as stated by the manufacturer. Finally, a possible uncertainty 
of δ5 = 1.0 mm was assigned again to the Vista scanner readout based on factors of the 
physical jar containing the ClearView gel. These sources and uncertainties are listed in 






Uncertainty Source δ (mm) 
Acrylic adapter alignment 1.0 
Winston-Lutz isocenter test 0.6 
CBCT registration 0.1 
VistaView scanner alignment 0.5 
VistaView scanner readout 1.0 
Standard deviation by quadrature 1.6 
Table 3: Evaluation 3 uncertainty sources and values 
The final standard deviation by quadrature value of δ= 1.6 mm was calculated in the 












Figure 7: ClearView gel after radiation delivery 
3.0 RESULTS 
3.1 Preliminary Observations 
Immediately after dose delivery, the purple-shaded formazan dye was clearly 
visible to the naked eye. As expected, darker shades of purple could be seen closer to the 
isocenter of the dose delivery [S]. In Figure 7below, the purple dye can be seen to be 




3.2.1 Evaluation 1 
 After receiving the VistaView files from Modus, the scan data was loaded to 
compare to the original treatment plan. Using the three reference planes (axial, coronal, 
sagittal), thedosimetry results were analyzed in relation to thetreatment plans used for 
delivery. For the single beam delivery from Evaluation 1, a side-by-side comparison of 
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each plane within the VistaView software shows an early visual compliance between the 
two data sets. The brighter red areas correlate to a higher dose received by the gel, where 




Figure 8: Evaluation 1 planned (left) and measured (right) dose 
distribution by plane. Top to bottom: sagittal (ZY), coronal (ZX), axial (XY) 
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From these visual comparisons in Figure 8 above, it is clear that the planned dose 
and measured dose show similarities in both shape and intensity. In addition to the 
expected dose distribution surrounding the isocenter, slight dose accumulation in the 
measured dose planes is visible. However, in order to determine the level accumulated in 
the shadowed regions and also verify geometric accuracy, line-dose profiles were used 
within the VistaView software across each axis to quantify the results of the dose 














































































For these three figures, the red data set represents the measured values obtained 
by the ClearView gel through the Vista scanner within its suggested dose range. The blue 
data set for each figure shows the planned dose across each axis. The error bars along 
each measured data set show the calculated margin of uncertainty (δ=1.6 mm) for each 
dose distribution, which was calculated in an earlier section. With the error bars in place, 
the dose distribution for the ClearView gel dosimeter falls within the range of acceptable 
values for Evaluation 1. 
3.2.2 Evaluation 2 
 The second evaluation was performed to determine the viability of ClearView gel 
as consisted of two arc beams delivering equal dosage to the gel. As before, the following 
figure shows a side-by-side comparison of the planned dose delivery to that recorded by 













Figure 12: Evaluation 2 planned (left) and measured (right) dose 
distribution by plane. Top to bottom: sagittal (ZY), coronal (ZX), axial (XY) 
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Once again, the above figure shows an early visual indication that the two data 
sets share similar shape and intensity relative to one another. The general shapes ofthe 
dose distributions between each of the corresponding three planes appear to exhibit the 
same falloffs and isocenters, with the measured dose planes again showing slight dose 
accumulation outside the targeted region. From these two data sets, three line-dose 














































































With the two arc beams, the results from the dosimeter very closely matched the 
treatment plan geometrically. As before, the red line represents the ClearView results 
within its suggested dose range of 10-80 Gy, and the blue line shows the original 
treatment plan. The error bars above represent the calculated margin of uncertainty 
(δ=1.6 mm) for each data point along the dosimeter curve. 
3.2.3 Evaluation 3 
 The third and final evaluation of this report examined the use of the ClearView 
gel in a full end-to-end SRS treatment. Using the same color-coding as in the previous 
two evaluations, I then measured and planned dose distribution were compared between 
the two data sets in the VistaView software. Figure 16 below shows the planned dose 




Figure 16: Evaluation 3 planned (left) and measured (right) dose 
distribution by plane. Top to bottom: sagittal (ZY), coronal (ZX), axial (XY) 
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The outlines of the jar containing the ClearView gel are purposely present in this 
evaluation to show the angled positioning of the jar within the head phantom in relation 
to the three reference planes. Within the jar, the dose distribution can be seen to line up 
very well, as was the case with both of the previous evaluations. A line-dose profile 
across each plane can quantify the data to determine accuracy of delivery. The following 














































































Figures 17 – 19 show the uncorrected data with uncertainty error bars for each 
line-dose profile. Each red line shows the measured results overlaid on top of the blue 
planned dose profile.For this evaluation, the uncertainty was determined to be 1.6 mm 
along the x-axis of each plot as determined earlier. Though this data does show that the 
measured dose distribution almost entirely fits within the acceptable range of error, the 
plots can be “corrected” by shifting the measured data sets within the acceptable range of 
uncertainty.This correction is not to minimize the visible shifts in data, but only to show 
the shapes of the spatial distributions in comparison to the planned profiles. The abscissa 












































































Planned Measured & Shifted
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These three plots may be more helpful in comparing the shape of the spatial 
distribution of the dose within the gel. Here, the X, Y, and Z axes were shifted by 0.40 
mm, 1.2 mm, and -0.50 mm respectively. As noted earlier, the Y-axis seemed to show the 
largest shift in data between the planned and experimental distributions, which can be 
seen by the first set of line-dose profiles and the required shift in Figure 19. However, 
with the dotted red lines representing the data after a maximum of 1.2 mm in abscissa 
shift, the shape of each data set is clearly a match with the planned line-dose profile 















4.1 Spatial Uncertainty 
 In this experiment, each evaluation’s results fell within the calculated uncertainty 
for their respective procedure. The calculation of these uncertainties as discussed in 
Section 2.6 closely follow those of AAPM Task Group 42, who determined an achievable 
SRS accuracy of 2.4 mm in their report [6]. With a maximum individual uncertainty of 
1.6 mm for each evaluation, the results of this evaluation fall well under acceptable limits 
for SRS. 
 For modern SRS treatments, similar calculations are used to determine the 
acceptable dose distribution based on three target volumes: gross tumor volume, clinical 
target volume, and planned target volume [35]. The gross tumor volume (GTV) is the 
extent of the tumor that can be imaged by conventional medical imaging techniques for 
treatment planning purposes. Surrounding the GTV is the clinical target volume (CTV), 
which not only includes the GTV, but also a localized region surrounding the GTV to 
account for the areas of the tumor that cannot be seen through imaging techniques.The 
volume encompassed in the CTV is typically a fixed value largely determined by the size 
of the GTV and the type of condition. 
Lastly, surrounding both the GTV and the CTV is the planned target volume 
(PTV). This third volume accounts for uncertainties encountered during treatment 
delivery such as tissue movement, delivery tolerances of the equipment used to provide 
the treatment, and other geometric sources of uncertainty. In order for successful 
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treatment, this volume must be carefully contoured to encompass the entire tumor while 
avoiding other structures and healthy tissue that could be adversely affected by treatment. 
For the acoustic neuroma condition simulated in this experiment, it is not 
uncommon for a 1-2 mm expansion of the PTV surrounding the tumor [36].Based on the 
acceptable amount of uncertainty calculated in this experiment, each test showed that the 
ClearView gel not only fell within these limits of geometric uncertainty, but also under 
the maximum amount typical of actual treatments for this condition. This compliance 
between both the experimental and clinical uncertainties shows promise that ClearView 
could be well suited for SRS commissioning and QA in terms of spatial resolution and 
geometric accuracy. 
4.2Accelerator Dose Levels 
Prior to the first dose delivery, the dose output accuracy of the TrueBeam 
accelerator was verified through several sequential measurements taken with an Exradin 
A16 ion chamber (Standard Imaging, Inc. - Middleton, WI) connected to a Capintec, Inc. 
(Ramsey, NJ) 192x Digital Dosimeter. From these measurements, the dose output of the 
accelerator was verified to have consecutive intensity measurements within 1% of each 
other.Throughout the course of the day, the readings are expected to remain within 2% of 
the morning test measurements. With the machine performing as expected, the dose 
discrepancy between the expected and measured data sets must lie somewhere within the 
procedure or the gel itself 
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As stated previously, the data used as a baseline for the scanner readings is a 
general calibration data set, which may vary from the accelerator used to irradiate the 
dosimeter.Gel batch variations also weigh heavily in the calibration data used to 
determine the dose received by the gel. Evaluation 3 showed much better response to the 
output of the TrueBeam system used in this experiment in comparison to both Evaluation 
1 and 2, which showed to vary up to ten percent at the reported isocenter. The change 
between the third evaluation and the first two may be a result of batch variation during 
chemical gel production. Efforts to reduce batch variation are currently in effect at the 
Modus production facility. 
Aside from the sources of uncertainty in the gel itself, other possible causes for 
the differences in reported dose levels are present. Differences in thickness and 
manufacturing of the vial containing the ClearView gelcan slightly affect the OD 
readings, which in turn could affect the measured dose level in the gel. Corrections for 
vial differences could be implemented once a baseline has been established for the CT 
scanner.The scanner can also have its output readings affected by the angle of the 
incident light to the curved surface of the vial, causing additional scatter in the OD 
measurement process. Again, corrections for these sources of uncertainty are currently 
being explored by the manufacturer. 
4.3Future Work 
 Though ClearView gel shows promise of use in SRS commissioning and QA, 
further tests could explore other aspects of the gel to ensure that is a suitable replacement 
for current methods. Experiments across a wider range of dose delivery techniques could 
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show if the gel experiences limitations for SRS QA testing. Although all the tests in this 
experiment were performed at the same beam energy for consistency between 
evaluations, testing across a wider range of beam energies and dose rates could 
demonstrate how the gel reacts in terms of possible energy or dose rate dependence 
typical of other dosimetry techniques. In addition, tests across various temperatures could 
determine if temperature during irradiation has any significant effects on the measured 
output of the gel.  
One alternative to relying solely on the ClearView gel dosimeter for not only 
spatial distribution but also absolute dose levels received by the gel is to use ClearView 
in addition to an output verification device. In this experiment, an Exradin A16 ion 
chamber was used prior to gel irradiation to determine the accuracy of the TrueBeam’s 
output. Though the ion chamber is poorly suited for SRS dosimetry, the information 
obtained from preliminary measurements with an ion chamber could be used to normalize 
the dose distribution curve to match the output of the delivery system. Though the 
ClearView gel would not be the sole instrument required for SRS commissioning and 
QA, it could serve as an integral part of the QA process as a whole. Further testing could 








 In this experiment, new ClearView gel dosimeterswere utilized to measure the 
output accuracy of a Varian TrueBeam particle accelerator. To test the dosimeter, three 
different evaluationswere performed that encompassed several factors of SRS: one static 
beam delivery, one full rotational arc about the central axis, and one full end-to-end SRS 
treatment plan simulating the treatment of an acoustic neuroma. The capabilities of the 
VistaView softwareallowed for direct comparison of the measured results obtained from 
the ClearView gel to the original treatment plans. 
Based on the composed line-dose profiles for each of the three evaluations, it 
wasverified that the tetrazolium salt-based ClearView gel dosimeter was geometrically 
accurate within the calculated window of uncertainty for every evaluation performed in 
this project.The sub-millimeter accuracy of the ClearView gel allows precise 
determination of the target isocenter after irradiation as well as how much additional dose 
is delivered to the surrounding tissue within the steep dose gradients. Though ClearView 
shows promise for SRS commissioning and QA due to its high spatial dose distribution in 
three dimensions, further testing of reported dose would be needed to verify its use as a 
standalone dosimeter for small field dosimetry. 
The capability to determine accurately measure spatial dose distribution for these 
small-field dose geometries suggests that ClearView could be applied to other treatment 
methods employing small-field dosimetry QA. Small-field volumetric modulated arc 
therapy (VMAT) and intensity modulated radiation therapy (IMRT) could be appropriate 
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